Literature DB >> 22871578

High-affinity and selective dopamine D₃ receptor full agonists.

Jianyong Chen1, Beth Levant, Shaomeng Wang.   

Abstract

We have designed, synthesized and evaluated a series of new compounds with the goal to identify potent and selective D(3) ligands. The two most potent and selective new D(3) ligands are compounds 38 and 52, which bind to the D(3) receptors with a K(i) value of <nM and display a selectivity of 450-494 times over the D(2) receptors and >10,000 times over the D(1) receptors. Both 38 and 52 are full agonists with high potency at the D(3) receptor in a D(3) functional assay.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871578      PMCID: PMC3461280          DOI: 10.1016/j.bmcl.2012.07.003

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  34 in total

1.  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.

Authors:  Peter Grundt; Katherine M Prevatt; Jianjing Cao; Michelle Taylor; Christina Z Floresca; Ji-Kyung Choi; Bruce G Jenkins; Robert R Luedtke; Amy Hauck Newman
Journal:  J Med Chem       Date:  2007-08-02       Impact factor: 7.446

2.  Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.

Authors:  Ke Ding; Jianyong Chen; Min Ji; Xihan Wu; Judith Varady; Chao-Yie Yang; Yipin Lu; Jeffrey R Deschamps; Beth Levant; Shaomeng Wang
Journal:  J Med Chem       Date:  2005-05-05       Impact factor: 7.446

3.  Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model.

Authors:  Dennis A Brown; Prashant S Kharkar; Ingrid Parrington; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.

Authors:  Swati Biswas; Stuart Hazeldine; Balaram Ghosh; Ingrid Parrington; Eldo Kuzhikandathil; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2008-04-12       Impact factor: 7.446

5.  Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.

Authors:  Jianyong Chen; Ke Ding; Beth Levant; Shaomeng Wang
Journal:  Bioorg Med Chem Lett       Date:  2005-11-14       Impact factor: 2.823

6.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

Authors:  C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

7.  Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.

Authors:  Min Ji; Jianyong Chen; Ke Ding; Xihan Wu; Judith Varady; Beth Levant; Shaomeng Wang
Journal:  Bioorg Med Chem Lett       Date:  2005-03-15       Impact factor: 2.823

8.  Dopamine D2, D3, and D4 selective phenylpiperazines as molecular probes to explore the origins of subtype specific receptor binding.

Authors:  Katharina Ehrlich; Angela Götz; Stefan Bollinger; Nuska Tschammer; Laura Bettinetti; Steffen Härterich; Harald Hübner; Harald Lanig; Peter Gmeiner
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile.

Authors:  Jianyong Chen; Gregory T Collins; Jian Zhang; Chao-Yie Yang; Beth Levant; James Woods; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-09-12       Impact factor: 7.446

10.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  2 in total

1.  Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.

Authors:  Amy E Moritz; R Benjamin Free; Warren S Weiner; Emmanuel O Akano; Disha Gandhi; Ara Abramyan; Thomas M Keck; Marc Ferrer; Xin Hu; Noel Southall; Joseph Steiner; Jeffrey Aubé; Lei Shi; Kevin J Frankowski; David R Sibley
Journal:  J Med Chem       Date:  2020-05-12       Impact factor: 7.446

Review 2.  Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches.

Authors:  Pedro Cruz-Vicente; Luís A Passarinha; Samuel Silvestre; Eugenia Gallardo
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.